Sida laga soo xigtay daraasad lagu daabacay joornaalka New England Journal of Medicine oo la daabacay July 5, Cabozantinib guud ahaan iyo badbaadada bilaashka ah ee bukaanada qaba kansarka hepatocellular sare ayaa aad uga fiicnaa kooxda placebo.
Dr. Ghassan K. Abou-Alfa oo ka socda Xarunta Kansarka Memorial Sloan ee Magaalada New York iyo asxaabtiisuba waxay kala sooceyn 707 bukaan oo qaba kansarka hepatocellular sare si ay u helaan kaarbotinib ama placebo ku habboon 2 ilaa 1 saamiga. Ka qaybgalayaashu waxay heleen daawaynta sorafenib waxayna lahaayeen horumar cudur ka dib hal ama in ka badan oo daawaynta habaysan ee kansarka hepatocellular.
Falanqaynta bartamihii dhexe ee qorshaha labaad, tijaabadu waxay muujisay in badbaadada guud ee carbotinib ay aad uga dheereyd tan placebo.
Cilmi baarayaashu waxay ogaadeen in badbaadada guud ee carbotinib iyo placebo ay ahaayeen 10.2 iyo 8.0 bilood, siday u kala horreeyaan (saamiga halista ee dhimashada wuxuu ahaa 0.76). Wixii carbotinib iyo placebo, badbaadada dhexdhexaadka ah ee bilaashka ah waxay ahayd 5.2 iyo 1.9 bilood, siday u kala horreeyaan. 68% iyo 36% bukaanada ku jira kooxda carbotinib iyo kooxda placebo waxay la kulmeen darajada 3 ama 4 dhacdooyin xun, siday u kala horreeyaan. Dhacdooyinka heerka sare ee ugu caansan waa dareenka timirta dhirta, dhiig karka, heerarka sare ee aspartate aminotransferase, daal iyo shuban, kuwaas oo dhamaantood ku badan carbatinib.
Qorayaashu waxay qorayaan, "Bukaannada qaba hepatocellular carcinoma ee horay loo daweeyay, daaweynta carbotinib waxay sababi kartaa guud ahaan badbaado guud iyo badbaadin la'aan-horumar la'aan marka loo eego placebo."
https://www.drugs.com/news/cabozantinib-improves-survival-advanced-hepatocellular-cancer-75490.html
